Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series by Cortazar, Frank B. et al.
RESEARCH ARTICLE Open Access
Combination therapy with rituximab,
low-dose cyclophosphamide, and
prednisone for idiopathic membranous
nephropathy: a case series
Frank B. Cortazar1*, David E. Leaf2, Charles T. Owens3, Karen Laliberte1, William F. Pendergraft III4
and John L. Niles1
Abstract
Background: Membranous nephropathy is a common cause of the nephrotic syndrome. Treatment with standard
regimens fails to induce complete remission in most patients. We evaluated the efficacy of combination therapy
with rituximab, low-dose, oral cyclophosphamide, and an accelerated prednisone taper (RCP) for the treatment of
idiopathic membranous nephropathy.
Methods: We analyzed 15 consecutive patients with idiopathic membranous nephropathy treated with RCP at
Massachusetts General Hospital. Seven patients (47%) received RCP as initial therapy, and the other eight patients
(53%) received RCP for relapsing or refractory disease. All patients had at least 1 year of follow-up. The co-primary
outcomes were attainment of partial and complete remission. Partial remission was defined as a urinary protein to
creatinine ratio (UPCR) < 3 g/g and a 50% reduction from baseline. Complete remission was defined as a UPCR < 0.
3 g/g. Secondary outcomes were serious adverse events and the change in proteinuria, serum creatinine, serum
albumin, cholesterol, triglycerides, and immunoglobulin G levels after 1 year of treatment.
Results: Over a median follow-up time of 37 (IQR, 34–44) months, 100% of patients achieved partial remission and
93% of patients achieved complete remission at a median time of 2 and 13 months, respectively. After 1 year of
treatment, median (IQR) UPCR declined from 8.2 (6.6–11.1) to 0.3 (0.2–0.7) g/g (P < 0.001). Three serious adverse
events occurred over 51 patient years. No patients died or progressed to ESKD.
Conclusions: Treatment of idiopathic membranous nephropathy with RCP resulted in high rates of complete
remission. Larger studies evaluating this regimen are warranted.
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Background
Membranous nephropathy (MN) is one of the most
common causes of the nephrotic syndrome [1]. Approxi-
mately 75% of MN cases are idiopathic [2]. The course
of idiopathic MN in patients not receiving immunosup-
pressive therapy is variable. Approximately 35% of patients
achieve complete or partial spontaneous remission, while
40% of patients ultimately progress to end-stage kidney
disease (ESKD) over a 10 year period [3, 4]. Risk factors
for progressive renal decline, and therefore treatment
with immunosuppression, include persistent proteinuria
of > 4 g per day despite treatment with an angiotensin
converting enzyme inhibitor (ACE-I) or angiotensin re-
ceptor blocker (ARB) and/or abnormal or worsening
estimated glomerular filtration rate (eGFR) attributed
to MN [5].
When immunosuppressive therapy is indicated, current
guidelines recommend the Ponticelli protocol, a 6-month
course of alternating monthly oral cyclophosphamide and
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corticosteroids [6, 7]. Alternatively, a calcineurin in-
hibitor-based regimen with or without low-dose prednis-
one is recommended if there is a desire to avoid an
alkylating agent [6]. Unfortunately, these regimens gener-
ally result in rates of complete remission of < 35% [7–10].
The M-type phospholipase A2 receptor (PLA2R), a
transmembrane protein expressed on glomerular podo-
cytes, has been demonstrated to be the target antigen in
most cases of idiopathic MN [11]. This creates a para-
digm whereby circulating autoantibodies to PLA2R form
in situ immune complexes at the level of the podocyte,
leading to the development of MN. The central mechanis-
tic role for autoantibodies in MN has provided a rationale
for B cell targeted therapy. However, monotherapy treat-
ment with rituximab, a monoclonal anti- CD20 antibody,
fails to induce complete remission in the vast majority
of patients [12–14].
In an attempt to more effectively induce remission
while allowing for a reduced exposure to high-dose glu-
cocorticoids, the practice pattern in our group for the
treatment of newly diagnosed, relapsing, and refractory
idiopathic MN evolved to become a three drug regimen:
rituximab dosed to maintain continuous B cell depletion,
a 2-month course of oral, low-dose, bridging cyclophos-
phamide, and an accelerated prednisone taper (RCP).
Given that MN is an antibody mediated disease, the prem-
ise of this regimen is to target plasma cells with cyclophos-
phamide and glucocorticoids while concurrently depleting
plasma cell precursors with rituximab. We present a retro-
spective analysis of the outcomes of 15 consecutive patients
treated with this regimen.
Methods
Patient selection
Starting in July of 2009, combination therapy with rituxi-
mab, glucocorticoids, and cyclophosphamide became the
preferred immunosuppressive regimen for patients pre-
senting to the Massachusetts General Hospital Vasculitis
and Glomerulonephritis Center with idiopathic MN. We
performed a retrospective analysis of patients treated
with this regimen who had biopsy-proven MN and met
at least one of the following criteria: 1) persistent urinary
protein to creatinine ratio (UPCR) > 4 g/g for > 6 months
despite treatment with an ACE-I or ARB; 2) declining
renal function, defined as a 30% rise in serum creatinine
from baseline attributed to MN; 3) debilitating or life
threatening symptoms due to the nephrotic syndrome; 4)
recurrence of a UPCR > 4 g/g following remission after a
prior immunosuppressive treatment; or 5) refractory dis-
ease, defined as failure of an alternative immunosuppres-
sive regimen to induce a partial remission after at least
6 months of therapy. Patients were considered to have the
nephrotic syndrome if they had a UPCR > 3.5 g/g, a serum
albumin < 3 g/dL, and peripheral edema.
As part of routine care, all patients were evaluated for
secondary causes of MN by age-appropriate cancer
screening, assessment for occult malignancy as indicated
based on history and physical examination, review of med-
ications for potential drug culprits, screening for hepatitis
B and C viruses, antinuclear antibody testing, and pursu-
ing additional testing as deemed appropriate by the treat-
ing nephrologist. After retrospective chart review, patients
were excluded from the analysis if they were found to have
a malignancy, active hepatitis B or C, lupus membranous,
or exposure to a medication known to cause MN. All pa-
tients with at least 1 year of follow-up were included in
the study. The study was approved by the Massachusetts
General Hospital Institutional Review Board.
Treatment regimen
A summary of the treatment regimen is shown in Fig. 1.
Cyclophosphamide was administered orally at 2.5 mg/kg
daily for 1 week, then 1.5 mg/kg daily for 7 weeks. The
dose of cyclophosphamide was adjusted for renal function
as follows: 10% dose reduction if the eGFR was 60–90 ml/
min/1.73 m2, 25% if the eGFR was 45–59 ml/min/
1.73 m2, 33% if the eGFR was 30–44 ml/min/1.73 m2, and
40% if the eGFR was 15–29 ml/min/1.73 m2. GFR was es-
timated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [15]. Concurrently
with the start of cyclophosphamide, patients were initiated
on rituximab with two 1000 mg intravenous doses sepa-
rated by approximately 2 weeks. Thereafter, patients re-
ceived rituximab 1000 mg IV every 4 months for 2 years
with the aim of maintaining continuous B cell depletion.
The rituximab dosing interval was based on data indicat-
ing that B cell reconstitution commences 16 weeks after
rituximab administration in a significant subset of
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Fig. 1 Schematic representation of treatment regimen.
Cyclophosphamide was administered orally at 2.5 mg/kg daily for
1 week, then 1.5 mg/kg for daily for 7 weeks. The cyclophosphamide
dose was adjusted for renal function as delineated in the methods.
Prednisone was initiated at 60 mg daily, tapered to 15 mg daily by
4 weeks, and then slowly tapered to complete a 6 month course as
described. Rituximab doses (arrows) were administered as 1000 mg
intravenously. Abbreviations: CYC, cyclophosphamide
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patients [16]. To ensure continuous B cell depletion was
achieved, peripheral blood was sent for flow cytometry
analysis immediately prior to each rituximab dose. Prednis-
one was tapered as follows: 60 mg daily for 1 week, 40 mg
daily for 1 week, 30 mg daily for 1 week, 20 mg daily for
1 week, and then a slow taper to complete a 6 month
course. Minor modifications of the treatment regimen
were permitted at the discretion of the treating physician.
Patients were typically seen in clinic at presentation,
1 week (first rituximab dose), 3 weeks (second rituximab
dose), 2 months, 4 months, and then every 4 months
during the active treatment phase. Following treatment,
patients were seen every 4 to 6 months for monitoring.
The following labs were checked at each visit: complete
blood count (CBC), comprehensive metabolic panel,
spot urine total protein, and spot urine creatinine. A
CBC was checked every 2–3 weeks while patients were
on cyclophosphamide to monitor for leukopenia. Lipids
were checked every 4 months. Peripheral blood was sent
for flow cytometry (to monitor for B cell depletion) and
serum immunoglobulins prior to each rituximab infusion.
Some patients were tested for antibodies to the M-type
phospholipase A2 receptor (PLA2R). Testing for antibodies
to PLA2R was performed on peripheral blood via enzyme-
linked immunosorbent assay (Euroimmun, Lubeck,
Germany) or from staining deposits on kidney biopsies
for PLA2R via immunofluorescence.
Primary outcomes
The primary outcomes were attainment of partial and
complete remission. Partial remission was defined as a
UPCR < 3.0 g/g and a ≥50% reduction in the UPCR from
baseline. Complete remission was defined as a UPCR <
0.3 g/g. Relapse after complete or partial remission was
defined as a UPCR > 3 g/g. All UPCRs were determined
with a spot collection.
Secondary outcomes
Secondary outcomes included the change in proteinuria,
serum creatinine, serum albumin, total cholesterol, triglyc-
erides, and immunoglobulin G levels from baseline to
1 year after treatment.
Serious adverse events
At each visit, patients were asked about any interval infec-
tions, hospitalizations, or other complications. All re-
ported adverse events were recorded in our electronic
treatment flowsheets. To ensure accuracy, we report only
serious adverse events, defined as those that were life
threatening or required hospitalization.
Statistical analysis
Analyses were carried out using STATA version 14
(College Station, Texas). Baseline characteristics are
presented as percentages or medians and interquartile
ranges (IQRs), and were compared using the Wilcoxon
rank-sum test or Fisher’s exact test, as appropriate.
Longitudinal differences in clinical parameters from
baseline to 1 year after initiation of treatment were ana-
lyzed with the Wilcoxon signed-rank test.
The Kaplan-Meier method was used to examine the
time to achieving a complete or partial remission. Time
to event was the time from initiation of treatment to the
attainment of complete or partial remission. The analysis
was stratified by disease status (initial presentation versus
relapsing/refractory disease). Differences between curves
were assessed using the log-rank test and proportional-
hazards model. All comparisons are two-tailed, with
P < 0.05 considered significant.
Results
Baseline characteristics
In September of 2015, 15 consecutive patients with idio-
pathic MN treated with rituximab, cyclophosphamide,
and prednisone (RCP) had at least 1 year of follow-up.
Seven patients (47%) received RCP as initial therapy.
The remaining eight patients (53%) were referrals from
other physicians who had been previously treated for
idiopathic MN and had relapsing or refractory disease.
Baseline characteristics overall and stratified by treat-
ment status are presented in Table 1.
The median age at presentation was 62 years (IQR,
45–67 years) and 53% of patients were female. The study
population consisted of 13 Caucasian patients, 1 black
patient, and 1 Hispanic patient. Baseline autoantibodies
to PLA2R were present in 4 of 5 patients with available
data. The most common treatment indication for patients
receiving RCP as initial therapy was debilitating symptoms
of the nephrotic syndrome. Patients receiving RCP as
second-line therapy were most commonly treated for a
disease relapse (UPCR > 4 g/g) occurring after prior dis-
ease remission induced by immunosuppression and failure
of 6 months of an ACE-I or ARB to result in a reduction
of UPCR to < 4 g/g. All patients receiving RCP as second-
line therapy and 1 patient receiving RCP as initial therapy
met more than 1 treatment indication.
The median UPCR was 8.2 (IQR, 6.8–11.4) g/g and
was similar in patients receiving RCP as initial versus
second-line therapy. The majority of patients in both
treatment groups had the nephrotic syndrome. Baseline
serum creatinine was higher in patients receiving RCP as
second-line therapy compared to initial therapy (median
[IQR], 1.3 [1.2–2.1] versus 0.8 [0.5–0.09] mg/dl, P = 0.011).
Three patients had an eGFR 30–60 ml/min/1.73 m2, and
two patients had an eGFR < 30 ml/min/1.73 m2.
Of the 8 patients who received prior treatment, 4
(50%) had been treated with 2 different treatment regi-
mens. The 8 patients with relapsing or refractory disease
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were exposed to 12 different treatment regimens. In
combination with prednisone, 3 patients were treated
with cyclophosphamide, 2 with mycophenolate mofetil,
3 with cyclosporine, and 1 with tacrolimus. Three pa-
tients received prednisone monotherapy.
The five patients treated with RCP for disease relapse
had a median immunosuppression-free interval of
18 months (IQR, 12 to 84 months). In all cases, the
UPCR at initiation of RCP was greater than the UPCR
6 months prior (median difference 1.5 g/g [IQR, 0.6 to
4.1 g/g]). The characteristics of patients treated for re-
fractory disease are presented in Table 2.
Primary outcomes
Median follow-up time was 37 (IQR, 34–44) months. All
patients achieved partial remission by 1 year. Median time
to achievement of partial remission was 2 (IQR, 1–7)
months (Fig. 2a). There was a trend toward faster in-
duction of partial remission in patients receiving RCP
as initial treatment versus second-line therapy (HR 3.2;
95% CI 0.9–10.6; P = 0.06, Fig. 2b).
Fourteen patients (93%) achieved complete remis-
sion at a median time of 13 (IQR, 12–17) months
(Fig. 2c). All 14 patients who achieved complete re-
mission had a subsequent confirmatory UPCR < 0.3 g/g
Table 1 Baseline characteristics
Variable Overall (n = 15) Initial therapy (n = 7) Second-line therapy (n = 8) P value
Age (years) 62 (45–67) 52 (39–62) 64 (57–67) 0.12
Female 8 (53) 5 (71) 3 (38) 0.32
Systolic BP (mmHg) 140 (124–148) 124 (114–140) 147 (135–164) 0.037
Diastolic BP (mmHg) 82 (72–86) 80 (67–86) 83 (79–89) 0.29
Serum Creatinine (mg/dL) 1.2 (0.8–1.5) 0.8 (0.5–0.9) 1.3 (1.2–2.1) 0.011
eGFR (ml/min/1.73 m2) 65 (40–100) 100 (62–123) 56 (29–66) 0.024
eGFR Group 0.45
> 60 ml/min/1.73 m2 10 (67) 6 (86) 4 (50)
30–60 ml/min/1.73 m2 3 (20) 1 (14) 2 (25)
< 30 ml/min/1.73 m2 2 (13) 0 (0) 2 (25)
UPCR (g/g) 8.2 (6.8–11.4) 6.9 (5.2–10.2) 10.1 (8.0–11.7) 0.15
UPCR group 0.41
< 4a 1 (7) 1 (14) 0 (0)
4–8 5 (33) 3 (43) 2 (25)
> 8 9 (60) 3 (43) 6 (75)
Nephrotic Syndromeb 13 (87) 7 (100) 6 (75) 0.47
Albumin (g/dL) 2.7 (2.5–2.8) 2.7 (2.5–2.8) 2.6 (2.4–3.1) 0.86
Total Cholesterol (mg/dL)c 350 (252–371) 341 (252–367) 371 (249–438) 0.34
Triglycerides (mg/dL)c 172 (122–270) 134 (77–192) 177 (155–546) 0.14
Time Since Biopsy Diagnosis (months) 9 (3–24) 3 (0.5–4) 23 (16–60) 0.011
On ACE-I or ARB 13 (87) 5 (71) 8 (100) 0.20
On Statin 8 (53) 2 (29) 6 (75) 0.13
Treatment Indications
Failure of ACE-I or ARBd 8 (53) 2 (29) 6 (75) 0.13
Declining Renal Function 5 (33) 1 (14) 4 (50) 0.30
Debilitating Symptoms from nephrotic syndrome 10 (67) 5 (71) 5 (63) 0.99
Relapsing Disease 6 (38) NA 6 (75) NA
Refractory Disease 3 (19) NA 3 (38) NA
Data are presented as median (interquartile range) and n (%)
Abbreviations: ACE-I angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, eGFR estimated glomerular filtration rate, UPCR urinary
protein: creatinine ratio
aThe patient with a UPCR < 4 g/g had decompensated nephrotic syndrome with refractory edema and an albumin nadir of 1.1 g/dL
bNephrotic syndrome was defined as urinary protein: creatinine ratio > 3.5 g/g, serum albumin < 3 g/dL, and peripheral edema
cOne patient in the second-line therapy group did not have baseline cholesterol or triglycerides
dFailure of ACE-I or ARB was defined as a persistent UPCR > 4 g/g despite at least 6 months of therapy
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(Additional file 1: Figure S1). The one patient who failed
to achieve complete remission had advanced CKD attrib-
uted to MN with an eGFR of 18 ml/min/1.73 m2 at initi-
ation of RCP. Like with attainment of partial remission,
there was a trend to more rapid induction of complete
remission in patients receiving RCP as initial therapy
(HR 2.7; 95% CI 0.8–8.5; P = 0.10, Fig. 2d). Antibodies
to PLA2R became undetectable after treatment with
RCP in the 3 patients with documented circulating anti-
bodies at baseline
Additional treatment was required in 2 patients
who had persistent nephrotic-range proteinuria at
their 4 month follow-up visit. Both of these patients
received an additional 2 month course of cyclophos-
phamide at 1 mg/kg and subsequently achieved
complete remission. One patient relapsed 9 months
after partial remission while B cells remained depleted,
but achieved complete remission after treatment
with an additional 1 month of cyclophosphamide at
1.5 mg/kg.
At last follow-up the full 2-year regimen was com-
pleted by 14 patients, 8 of whom had relapsing or re-
fractory disease. Following completion of the 2-year
regimen, one relapse occurred over 20 patient-years
of treatment-free follow-up (median treatment-free
follow-up, 13.7 [IQR, 10 to 19] months). The relapse
occurred 4.8 years after the patient’s last rituximab
dose. At the time of relapse, B cells had reconstituted
and accounted for 16.7% of the lymphocyte pool. This
patient was treated with an 8 week course of cyclo-
phosphamide at 1.5 mg/kg, a rapid prednisone taper,
and two doses of rituximab 1000 mg IV separated by
2 weeks. The patient was back in complete by remis-
sion by 6 months.
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Fig. 2 Kaplan-Meier curves for partial and complete remission. Kaplan-Meier curves for the overall group and stratified by treatment status are
shown for partial remission (panels a and b) and complete remission (panels c and d). Abbreviations: HR, hazard ratio; IT, initial therapy;
SLT, second-line therapy
Table 2 Characteristics of patients with refractory disease
Patient Regimen Duration of
therapy (mos)
UPCR 6 months
before RCP
UPCR at RCP
initiation
1 MMF & Pred 12 5.2 10.7
2 CsA & Pred 18 NA 11.9
3 CsA & Pred 6 6.8 16.7
Abbreviations: CsA cyclosporine, MMF mycophenolate mofetil, mos months,
NA not available, Pred prednisone, UPCR urinary protein: creatinine ratio,
RCP rituximab, cyclophosphamide, prednisone
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Secondary outcomes
Response to treatment with RCP at 1 year, both overall
and stratified by treatment status, is shown in Table 3.
UPCR fell from a median of 8.2 (IQR, 6.6–11.1) to 0.3
(IQR, 0.2–0.7) g/g (P < 0.001, Fig. 3).
Overall, there was no change in serum creatinine at
1 year. However, in patients receiving RCP as second-
line therapy, there was a significant fall in serum cre-
atinine (1.3 [IQR, 1.2–2.1] to 1.2 [IQR, 1.1 to 1.7] mg/dL;
P = 0.02). There was a significant rise in serum albumin
and a significant decline in cholesterol in both treatment
groups (Table 3). Despite treatment with rituximab, there
was a significant rise in IgG levels (314 [IQR, 199–551] to
730 [IQR, 538–908] mg/dL; P = 0.003) due to a reduction
in urinary losses.
Ten patients had at least 1 year of follow-up after
completion of the 2-year RCP regimen. There was no
difference in UPCR or serum creatinine 1 year after
treatment completion compared with 1 year after treat-
ment initiation (Table 4).
Serious adverse events
Over a combined follow-up time of 51 patient years, three
serious adverse events (SAE) s occurred. Two SAEs, an
episode of late-onset neutropenia and a febrile viral syn-
drome, were felt to be potentially treatment-related. Both
events occurred in patients receiving RCP as second-line
therapy. The episode of late-onset neutropenia occurred
3.7 months after the patient’s 6th rituximab dose and
promptly responded to treatment with filgrastim. The pa-
tient subsequently received two additional doses of rituxi-
mab without incident. The patient with a viral syndrome
was hospitalized for evaluation of fever and malaise. An
infectious workup, including blood and urine cultures,
was negative and the symptoms resolved with only sup-
portive care. A specific virus was not isolated, but the
course was most consistent with a viral process.
The third SAE was an episode of altered mental status
that occurred after the initiation of high-dose gabapentin.
The patient’s mental status returned to baseline following
withdrawal of gabapentin, and this SAE was not felt to be
a consequence of MN or the RCP regimen. No patients
died or progressed to ESKD.
Discussion
Treatment with RCP was effective at inducing remission
in patients with idiopathic MN. In patients treated for at
least 1 year, 100% achieved partial remission and 93%
achieved complete remission. The response was durable,
with only 1 patient sustaining a relapse after completion
of treatment. Furthermore, achieving complete remission
appears to be time-dependent, with most individuals
achieving complete remission greater than 1 year after
initiating therapy. However, treatment with a standard
regimen of an alkylating agent and glucocorticoids gen-
erally achieves complete remission in less than 35% of
patients, even after extended follow up [3, 7, 9]. Simi-
larly, in a report of 100 patients with MN treated with
rituximab monotherapy, complete remission occurred in
fewer than 30% of patients [14].
Despite the limited sample size, our results suggest
that rates of remission achieved with RCP may be super-
ior to other treatment regimens that have been reported.
We attribute the success of the regimen to a multi-
targeted approach to halt the production of pathogenic
antibodies causing MN. Specifically, prednisone and
cyclophosphamide target plasmablasts and plasma cells,
while rituximab depletes the B cell pool required to
replete the plasma cell population. By administering ri-
tuximab every 4 months, B cells are prevented from re-
constituting. Standard cytotoxic regimens for MN can
be circumvented if plasmablasts and plasma cells produ-
cing pathogenic antibody are restored from the B cell
population. Likewise, rituximab monotherapy is unlikely
to be effective if long-lived plasma cells are participating
in the disease process.
We hypothesize that the long duration of B cell deple-
tion with RCP will lead to a more sustained remission
Table 3 Response to treatment at 1 year
Overall (n = 15) Initial therapy (n = 7) Second-line therapy (n = 8)
Variable Baseline 1-Year P value Baseline 1-Year P value Baseline 1-Year P value
UPCR (g/g) 8.2 (6.6–11.1) 0.3 (0.2–0.7) <0.001 6.9 (5.2–10.2) 0.2 (0.1–0.5) 0.02 10.1 (8–11.7) 0.6 (0.3–0.7) 0.01
Creatinine (mg/dL) 1.2 (0.8–1.5) 1.0 (0.8–1.2) 0.44 0.8 (0.5–0.9) 0.8 (0.7–1.0) 0.13 1.3 (1.2–2.1) 1.2 (1.1–1.7) 0.02
Albumin (mg/dL) 2.7 (2.5–2.8) 4.2 (4–4.4) <0.001 2.7 (2.5–2.8) 4.2 (3.9–4.4) 0.02 2.6 (2.4–3.1) 4.2 (4.0–4.4) 0.01
Cholesterol (mg/dL)a 350 (252–371) 189 (148–220) 0.001 341 (252–367) 167 (128–191) 0.02 371 (249–438) 207 (155–251) 0.02
Triglycerides (mg/dL) 172 (122–270) 189 (148–220) 0.40 134 (77–192) 105 (80–244) 0.74 177 (155–546) 182 (152–204) 0.24
IgG (mg/dL)b 314 (199–551) 730 (538–908) 0.003 499 (296–731) 806 (676–1027) 0.02 199 (198–308) 611 (364–676) 0.08
Data are presented as median (interquartile range). Baseline and 1 year values compared with Wilcoxon signed-rank test
a1 patient in the second-line therapy group did not have baseline cholesterol or triglycerides
bthree patients in the second-line therapy group had missing baseline IgG
Abbreviations: IgG immunoglobulin G, UPCR urinary protein:creatinine ratio
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compared with alternative regimens. Following comple-
tion of the RCP regimen, 1 relapse occurred over 20
patient-years in a population enriched in patients with
relapsing and refractory disease. Prior studies using cyto-
toxic therapy with prednisone have resulted in relapse
rates of approximately 30% by 1.5 years, and the relapse
rate approaches 45% for calcineurin inhibitor-based regi-
mens [7, 8]. More data and longer follow-up are needed
to more accurately define the relapse rate associated
with RCP. The optimal treatment regimen for patients
with relapsing disease following RCP is unknown. The
one patient who sustained a relapse after a treatment-
free interval of 4.8 years was successfully retreated with
the RCP regimen. It is possible that early and non-severe
relapses may respond well to rituximab alone.
The high rate of complete remission in patients
treated with RCP is likely to lead to long-term clinical
benefit. Patients attaining complete remission have an
excellent renal prognosis and a significantly lower rate
of reaching ESKD than those who achieve only partial
remission [17, 18]. In one analysis of 348 MN patients
with a median follow-up time of 6 years, none of the
102 patients with complete remission progressed to
stage V CKD, whereas 9% of the 132 patients with partial
remission progressed to stage V CKD [17]. Likewise, the
slope of renal decline was significantly flatter in patients
who achieved complete remission [17]. Additionally,
since albuminuria is a strong independent risk factor for
coronary artery disease and stroke, maximizing the re-
duction of proteinuria in patients with MN with RCP
may have important extra-renal benefits as well [19].
There may be concern that the simultaneous use of 3
immunosuppressive medications will lead to an in-
creased risk of infectious complications and other
Fig. 3 Change in proteinuria after 1 year of treatment. Data are depicted for patients receiving RCP as initial therapy (panel a) or as second-line
therapy (panel b). Abbreviations: UPCR, urinary protein:creatinine ratio
Table 4 Response to treatment at 3 years
Variable 1 year after RCP
initiation (n = 10)
1 year after RCP
completion (n = 10)
P value
UPCR (g/g) 0.3 (0.2–0.7) 0.1 (0.1–0.2) 0.09
Albumin (mg/dL) 4.2 (4.0–4.4) 4.6 (4.3–4.7) 0.036
Creatinine (mg/dL) 1.0 (0.8–1.2) 1.1 (0.8–1.3) 0.11
Data are presented as median (interquartile range) for the 10 patients with
1 year of treatment-free follow-up. Values 1 year after RCP initiation were
compared to values 1 year after RCP completion with the Wilcoxon
signed-rank test
Abbreviations: UPCR urinary protein:creatinine ratio, RCP rituximab,
cyclophosphamide, prednisone
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adverse events. In our study, three serious adverse events
occurred over 51 patient years. This regimen allows for
a rapid prednisone taper in which patients are reduced
to a dose of 15 mg per day by 4 weeks. Moreover, the
cumulative dose of cyclophosphamide used in this regi-
men (97 mg/kg prior to renal adjustment) is significantly
less than in other regimens for MN. For example, in the
Ponticelli regimen, patients receive a total of 180 mg/kg
of cyclophosphamide. Adjustment of the cyclophospha-
mide dose for renal function likely serves to further miti-
gate potential side effects. The risk of urothelial
carcinoma is dose-dependent, and is unlikely to occur
with the doses used in our regimen [20, 21]. Cyclophos-
phamide has also been associated with the development
of myelodysplastic syndrome, leukemia, and other malig-
nancies in a dose-dependent fashion [22, 23] . However,
cyclophosphamide in the RCP regimen is used for a
shorter duration and at a lower dose than conventional
regimens used for the treatment of renal or rheumato-
logic diseases. Thus, while it is difficult to estimate the
exact risk of malignancy with RCP, it is likely lower than
the incidence associated with other cyclophosphamide-
based regimens.
Rituximab in our protocol was dosed every 4 months
for 2 years with the aim of maintaining continuous B cell
depletion. This represents a longer duration of therapy
than other regimens using rituximab for idiopathic MN
[12–14, 24]. Our rationale was that more prolonged
therapy would lead to a higher rate of complete remis-
sion and lead to lower rates of relapse without a signifi-
cant increase in adverse events. Indeed, achieving
complete remission appeared to be time-dependent, with
most individuals achieving complete remission greater
than 1 year after initiating therapy. Moreover, the re-
sponse appeared durable with only 1 patient sustaining a
relapse after complete remission was attained. A prior
investigation of 173 patients with ANCA vasculitis dem-
onstrated that rituximab-induced continuous B cell de-
pletion for a median duration of 2.1 years was safe and
effective with survival that mirrored that of the general
population [25]. While the RCP regimen was well toler-
ated during the observation-period, we cannot exclude
the possibility of treatment-related side effects develop-
ing in the future.
Our study has several important limitations. Patient
selection in studies of MN is important to consider given
the possibility of spontaneous remission in low-risk pa-
tients [2]. Inclusion of patients with a higher probability of
spontaneous remission can result in overestimation of
treatment efficacy. Of note, our study population was
enriched in women compared to the male predominance
typically observed in MN. There is evidence that female
patients may have a better prognosis and a higher rate of
spontaneous remission [26, 27]. In addition, some patients
receiving RCP as initial therapy were treated early in their
disease course due to debilitating nephrosis, and we
cannot exclude the possibility that a subset would have
remitted spontaneously. However, 50% of the patients
in our study had relapsing or refractory disease, and the
high-grade baseline proteinuria (median UPRC of 8.2 g/g)
decreases the probability of spontaneous remission [28].
Moreover, the rate of spontaneous complete remission in
idiopathic MN is low. In an observational study of 100 pa-
tients with predominantly low-risk disease, only approxi-
mately 10% of patients achieved complete remission by
2 years [29]. Thus, it is unlikely that the high rates of re-
mission that we observed with RCP can be attributed to
spontaneous remissions.
The discovery of antibodies to PLA2R as the inciting
event in the majority of cases of idiopathic MN has
greatly advanced the mechanistic understanding of the
disease [11]. In addition, a decline in anti-PLA2R anti-
bodies following treatment with rituximab predicts, and
typically precedes, clinical response [30]. Although
treatment with RCP led to undetectable PLA2R anti-
bodies in the three patients with documented baseline
circulating antibodies, our limited data precluded a ro-
bust analysis of clinical response with a change in anti-
body titers.
An additional limitation is that a spot UPCR, rather than
a 24-h urine collection, was used to quantify proteinuria.
This study is a retrospective analysis of patients undergoing
routine clinical care, a setting in which the 24-h urine col-
lection is cumbersome and often collected inappropriately.
The UPCR has excellent correlation with 24-h urine collec-
tion [31]. However, the UPCR is subject to more intra-
person variability and is influenced by the rate of urinary
creatinine excretion [32]. Nonetheless, all patients who
achieved complete remission had multiple subsequent
UPCR values of < 0.3 g/g after attaining complete remis-
sion. Given the repeated confirmation of complete remis-
sion in our patients, it is unlikely that the variability of the
UPCR significantly influenced the results.
Finally, the study is single-center, of limited size, and
lacks a comparator group. Statistical results must be
interpreted with caution in this setting. Larger studies
are required to confirm our findings.
Conclusions
In summary, RCP was effective and safe for the treatment
of idiopathic MN and may allow for a remission rate su-
perior to existing regimens. Over a median follow-up time
of 37 months, 100% of patients achieved partial remission
and 93% of patients achieved complete remission. In
addition, outcomes were similar regardless of incident or
relapsing disease. Larger studies comparing RCP to estab-
lished treatments are needed to further assess the utility of
this regimen in the treatment of idiopathic MN.
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Additional file
Additional file 1: Figure S1. Change in proteinuria with treatment.
Data are depicted for patients receiving RCP as initial therapy (panel A) or
as second-line therapy (panel B). One patient (Patient 9 in panel B) did
not achieve complete remission. After achieving complete remission, all
patients had a subsequent urinary protein:creatinine ratio < 0.3 g/g.
Abbreviations: UPCR, urinary protein:creatinine ratio. (DOCX 55 kb)
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